Lophius Biosciences, a developer of T-cell based test systems for infectious immunology diagnosis, has secured the US Patent US 78293318 entitled 'Use of urea-adjuvanted polypeptides for diagnosis, prophylaxis and therapy.'
The patent represents a key building block with respect to Lophius Biosciences T-cell based proprietary Urea technology platform, which has been used by the company already for the development of its diagnostic T-Track Tx test.
The test allows the broad and highly sensitive monitoring of cell-mediated immunity (CMI) in immunosuppressed transplant patients and acorresponding patent has been granted in the EU already and is nationalised in major markets.
Lophius Biosciences CEO Michael Lutz said that following the positive decision by the US patent office in early 2010 with respect to patent granting for their proprietary Reverse T-Cell technology, they are delighted to possess broad patent protection for the UREA technology platform in the markets worldwide.
Lophius Biosciences chief scientific officer Deml said that the Urea technology is a novel platform which enables parallel stimulation of a broad spectrum of clinically relevant immune cells based on its unique mechanism of action.
“For the 1st time, this allows the development of in vitro diagnostic products that are capable to mimic and evaluate the critical in vivo cellular immune functions. Furthermore, this technology also potentially opens up the opportunity to develop novel adjuvant-free vaccines with a strongly improved profile,” Deml said.